Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Vasculitis 1Urogenital Neoplasms 1Syndrome 1Stroke 1Stevens-Johnson Syndrome 1Pemphigoid, Benign Mucous Membrane 1Melanoma 1Inflammatory Bowel Diseases 1Hematologic Neoplasms 1Granulomatous Disease, Chronic 1Cytokine Release Syndrome 1Crohn Disease 1Colitis 1Carcinoma, Non-Small-Cell Lung 1Aneurysm 1

Interventions

Cyclophosphamide 19fludarabine 18Tacrolimus 10Whole-Body Irradiation 9Mycophenolic Acid 8venetoclax 7fludarabine phosphate 7Sirolimus 7Azacitidine 7Mesna 5Dexamethasone 5Bortezomib 5Rituximab 4Methotrexate 4Busulfan 4daratumumab 3Stem Cell Transplantation 3Peripheral Blood Stem Cell Transplantation 3Nivolumab 3Melphalan 3Lenalidomide 3Filgrastim 3Cytarabine 3Biopsy 3Alemtuzumab 3AP 1903 reagent 3pomalidomide 2merphos 2isatuximab 2ibrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Hematologic Neoplasms × Infliximab × Clear all
NCT04082910 2022-04-13

Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells

Chinese PLA General Hospital

Phase 1/2 Unknown
30 enrolled
Other hematologic neoplasm

Cytokine Release Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡